Coralgables, Florida
- Featured
Hypertension
* Condition: Hypertension * Clinical Trial Identifier: NCT04936035 * Sponsor: Alnylam Pharmaceuticals Looking for participants within a 30 mile radius of the study site.
Phase
2Span
Sponsor
Alnylam PharmaceuticalsCoral Gables, Florida
Recruiting
- Featured
Hypertension
* Condition: Hypertension * Clinical Trial Identifier: NCT05103332 * Sponsor: Alnylam Pharmaceuticals Looking for participants within a 30 mile radius of the study site.
Phase
2Span
Sponsor
Alnylam PharmaceuticalsCoral Gables, Florida
Recruiting
- Featured
Pneumococcal Infection
* Condition: Pneumococcal Infection * Clinical Trial Identifier: NCT05158140 * Sponsor: Merck Sharp & Dohme Corp. Looking for participants within a 30 mile radius of the study site.
Phase
3Span
Sponsor
Merck Sharp & Dohme Corp.Coral Gables, Florida
Recruiting
- Featured
Integument-PED study
The study drug consists of a cream of the medication or a placebo (same cream without the active drug) that will be applied once daily for 28 days. This treatment is experimental, and you (or your child) will have 1 in 2 chances to be part of the placebo part of the study. At the end of the study, participants may be eligible to participate in the open-labeled study, which would allow the participants to continue to receive the study treatment. More information will be made available to the participants should they be interested. Blood samples will be collected on screening, day 1 and week 4. If you consent to medical photography, it will be performed at day 1, week 1 and week 4. For more information and to register to the study, please visit the study page: http://eczema-study.com/
Phase
3Span
Sponsor
ArcutisCoral Gables, Florida
Recruiting
- Featured
Integument-1 study
The study drug consists of a cream of the medication or a placebo (same cream without the active drug) that will be applied once daily for 28 days. This treatment is experimental, and you (or your child) will have 1 in 2 chances to be part of the placebo part of the study. At the end of the study, participants may be eligible to participate in the open-labeled study, which would allow the participants to continue to receive the study treatment. More information will be made available to the participants should they be interested. Blood samples will be collected on screening, day 1 and week 4. If you consent to medical photography, it will be performed at day 1, week 1 and week 4. For more information and to register to the study, please visit the study page: http://eczema-study.com/
Phase
3Span
Sponsor
ArcutisCoral Gables, Florida
Recruiting
- Featured
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, as well as up to 3.5-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous nonsteroidal anti-inflammatory drug (NSAID), disease-modifying antirheumatic drug (DMARD) therapy and/or previous anti-tumor necrosis factor alpha (TNFa) therapy. Novartis Pharmaceuticals 1-888-669-6682 ClinicalTrials.gov identifier: NCT01989468
Phase
3Span
Sponsor
NovartisPonce, XX
Recruiting
- Featured
Integument-2 study
The study drug consists of a cream of the medication or a placebo (same cream without the active drug) that will be applied once daily for 28 days. This treatment is experimental, and you (or your child) will have 1 in 2 chances to be part of the placebo part of the study. At the end of the study, participants may be eligible to participate in the open-labeled study, which would allow the participants to continue to receive the study treatment. More information will be made available to the participants should they be interested. Blood samples will be collected on screening, day 1 and week 4. If you consent to medical photography, it will be performed at day 1, week 1 and week 4. For more information and to register to the study, please visit the study page: http://eczema-study.com/
Phase
3Span
Sponsor
Coral Gables, Florida
Recruiting
- Featured
Early Onset Alzheimer's Disease study
Study schedule: At the start of the study: -You will have a screening telephone call. -You will have in-person cognitive and neurological assessments. -You will give a blood sample. During the study: -You will have a follow-up telephone interview every 18 months. -You will repeat some or all of the study-start activities. Study activities may include: -Talking on the telephone. -Having cognitive and neurological assessments, which may be in the form of interview-style conversations, paper-and-pencil questionnaires, computer tests, and/or other activities. -Having a sample of blood drawn from your vein using a needle. Treatment or experiment details: -This study is interested in the genetic factors that influence early-onset Alzheimer’s. -There is no experiment or treatment being tested in this study. Additional details: -Nuclear families (parent, child, siblings) as well as extended families (grandparental, cousins, uncle/aunt, etc.) may be eligible. -Multiple family members must participate in the study together.
Phase
N/ASpan
Sponsor
Virtual Location
Recruiting
Healthy Volunteers
- Featured
Genetic Studies in Familial Dementia
Phase
N/ASpan
962 weeksSponsor
University of MiamiMiami, Florida
Recruiting
Healthy Volunteers
Coral Gables, Florida
Recruiting